July 6, 2015 /PRNewswire/ -- Moerae Matrix, a clinical stage biotechnology company focused on developing novel therapeutics that target inflammation and fibrosis, today announced the appointment of Bill Bradford, M.
As a leader and widely-respected peer in the pulmonary community based on his pioneering development work in Idiopathic Pulmonary Fibrosis, Bill will be a valuable addition to the Moerae team as we move our platform of MAPKAP Kinase 2 inhibitors forward," said Cynthia Lander, PhD, Moerae's Chief Executive Officer.
This first-in-human Phase 1 MMI-0100 study represents a significant milestone in achieving Moerae's corporate goal of developing novel, safe and effective compounds to alleviate suffering for the hundreds of thousands of patients worldwide who are afflicted with IPF and other fibrotic disorders," said Cynthia Lander, PhD, Chief Executive Officer of Moerae.
In addition to MMI-0100, Moerae has a pipeline of cell permeant peptide drug candidates being investigated for various diseases characterized by inflammation and fibrosis (e.
Presenters confirmed to date include AVAcore Technologies, Cardiac Output Technologies, Cohera Medical, CoreSpine Technologies, Deca-Medics, eCardio Diagnostics, EyeTect, HealthLink Europe, Infrared Sciences, Light Sciences Oncology, Moerae
Matrix, Nesos Health, Photo Dynamic Therapy, Portland Orthopaedic, Praxim, Provista Life Sciences, TheraCardia, and ValveXchange, among many others being added to the program regularly.
Presenters confirmed to date include AVAcore Technologies, Cardiac Output Technologies, CoreSpine Technologies, eCardio Diagnostics, HealthLink Europe, Light Sciences Oncology, Moerae
Matrix, Nesos Health, Photo Dynamic Therapy, Portland Orthopaedic, and ValveXchange, among many others being added to the program regularly.